Zhongnan Medical Journal Press

Home Results

A total of 12 result was found. Results that relate to ZHANG Wen

Review and risk information management of neuropathy induced by emerging anti-tumor drugs

Published on Chinese Journal of Pharmacoepidemiology 2024,33(1):9-18.
13192 times 2573 times

LYU Feng SONG Wei XIN Mengru XIE Di ZHANG Wenqing HE Wen HU Hankun

Emerging anti-tumor drugs Drug-induced neuropathy Drug risk information management
Details
Correlation study of neutrophils in knee osteoarthritis

Published on New Medicine 2024,34(3):347-354.
12644 times 2818 times

LIU Xin GUO Jiajun MA Hong'e ZHANG Wenxian

Knee osteoarthritis Neutrophils MicroRNAs Exosomes Treatment
Details
Efgartigimod alfa in the treatment of generalized myasthenia gravis: a rapid health technology assessment

Published on Chinese Journal of Pharmacoepidemiology 2024,33(10):1156-1163.
13187 times 2866 times

HUANG Gerile LI Yujie ZHANG Wenjing GUO Hao

Efgartigimod alfa Myasthenia gravis Rapid health technology assessment Efficaey Safety Economy
Details
Signal mining and analysis of adverse events for lecanemab based on the FAERS database

Published on Chinese Journal of Pharmacoepidemiology 2025,34(2):166-174.
13986 times 2523 times

ZHANG Wen LI Min LIU Erping TAO Wenting CAI Rui ZHOU Weixian

Lecanemab FAERS database Drug adverse events Signal mining
Details
Dorzagliatin in the treatment of type 2 diabetes：a rapid health technology assessment

Published on Chinese Journal of Pharmacoepidemiology 2025,34(4):448-455.
21397 times 4023 times

LI Yujie ZHANG Wenjing YANG Hongxin GUO Hao

Dorzagliatin Type 2 diabetes mellitus Rapid health technology assessment Efficacy Safety Economy
Details
Trends in the burden of spinal cord injury in China from 1990 to 2021

Published on New Medicine 2025,35(7):810-818.
18200 times 2470 times

CAI Yan CHEN Yuan ZHANG Wenxi

Disease burden Spinal cord injury Age-standardized incidence rate Age-standardized prevalence rate Age-period-cohort effect Trend analysis
Details
Search strategies for systematic review and Meta-analysis: from PICO to large language models

Published on Journal of Mathematical Medicine 2026,39(1):2-11.
6220 times 1569 times

HUANG Sidie CUI Nuan ZHANG Wen ZENG Yidi LI Lin LI Jinxia LIANG Hao

Systematic review Meta-analysis Retrieval strategy PICO Large language models
Details
Mepolizumab for refractory chronic rhinosinusitis with nasal polyps: a rapid health technology assessment

Published on Chinese Journal of Pharmacoepidemiology 2026,35(2):192-199.
8363 times 1526 times

GU Shilong ZHANG Wenjing GUO Hao

Mepolizumab Refractory chronic rhinosinusitis with nasal polyps Effectiveness safety Cost-effectiveness
Details
Construction of a risk prediction model for fertility anxiety in female thyroid cancer patients of reproductive age

Published on New Medicine 2026,36(4):399-406.
3413 times 1230 times

PENG Jingjun PENG Yuxia ZHANG Wenling HONG Xiaoting LI Yuyu

Reproductive age Thyroid cancer Fertility anxiety Risk prediction model
Details
The interaction effect of family function and school life satisfaction on depression and anxiety of youth in school

Published on New Medicine 2026,36(5):503-510.
2409 times 791 times

CHEN Yuanfan ZHANG Wenge TAN Jianfeng WU Jiayuan HU Liren

Family function School life satisfaction Youth Depression Anxiety
Details
Post-marketing safety evaluation of nirsevimab based on the FAERS database

Published on Chinese Journal of Pharmacoepidemiology 2026,35(6):653-659.
3348 times 841 times

NIU Rui LIU Wei ZHAO Kai ZHANG Wenqian ZHAO Fang

Nirsevimab Respiratory syncytial virus Pharmacovigilance Adverse drug reactions
Details
Meta-analysis of efficacy and safety of pertuzumab biosimilars versus original drug in the treatment of patients with HER2-positive breast cancer

Published on Chinese Journal of Pharmacoepidemiology 2026,35(7):810-817.
2640 times 825 times

GU Shilong ZHANG Wenjing GUO Hao

Pertuzumab Biosimilars Original drug HER2 Breast cancer Efficacy Safety Meta-analysis
Details